The granting of a European patent for a treatment targeting tau aggregates, a key factor in Alzheimer's disease, directly impacts AC Immune by potentially enhancing its product pipeline and positioning in the neurodegenerative disease treatment market. This development is likely to be viewed positively by investors, as it represents progress in a critical area of unmet medical need, thereby potentially increasing the company's value in the short term.